looked into that but what I got was more of an institution buy than a little guy they get the IPO :shrug:
shippers need to move for the economy to grow think it's time :0corn
Stock Market Thread - ALL COMBINED
- Thread starter vinnie
- Start date
looked into that but what I got was more of an institution buy than a little guy they get the IPO :shrug:
shippers need to move for the economy to grow think it's time :0corn
plenty of little guys buying it and selling it all day :shrug:
shippers are still on my watch lists too.
Good Luck I wish I was the little guy that held Ford @ buck or two
& I sold GSL Short BigTime Too :sadwave:
I just sold at $35.55 and made about $300. you're right about the big boys and i don't want no part of it when they decide to short it and that will be coming in a few days or weeks for sure.Good Luck I wish I was the little guy that held Ford @ buck or two
& I sold GSL Short BigTime Too :sadwave:
Nice move, idiot :nooo:
Have fun having 50K tied up until you get even. Sucked right in like an amateur :0074
:facepalm:
they won't lose on the IPO if they don't get the pop they will get it on the short :shrug:
I don't think there are short shares available for 30 days on an IPO.
But you're right, they always get theirs.
Union sold today to recover their loss.
http://blogs.forbes.com/joannmuller/...rtner=yahootix
"The trust, known as the GM Voluntary Employee Benefits Association, or VEBA, sold 102 million GM shares, or a third of its stake in GM, for $33 each. (The Treasury sold 412 million shares, netting $13.6 billion.) The VEBA will break even on its investment if it can sell the remaining 206 million shares at an average price of $36.96.
There?s a decent chance it will: on the first day of trading Thursday, GM stock traded as high as $35.99, before closing at $34.19. More than 450 million shares changed hands."
http://blogs.forbes.com/joannmuller/...rtner=yahootix
"The trust, known as the GM Voluntary Employee Benefits Association, or VEBA, sold 102 million GM shares, or a third of its stake in GM, for $33 each. (The Treasury sold 412 million shares, netting $13.6 billion.) The VEBA will break even on its investment if it can sell the remaining 206 million shares at an average price of $36.96.
There?s a decent chance it will: on the first day of trading Thursday, GM stock traded as high as $35.99, before closing at $34.19. More than 450 million shares changed hands."
US Starts Human Trial Of Embryonic Stem Cells On BlindnessLast update: 11/22/2010 12:39:57 AMWASHINGTON (AFP)--Human embryonic stem cells were set to be tested as a treatment for blindness, a U.S. company announced Monday in the second such clinical trial to examine how the controversial process works in people. Just 12 adult patients were set to take part in the trial to determine how the treatment using retinal cells, derived from human embryonic stem cells, affects patients with a common form of vision loss that takes hold in children as young as six. The process has been tested on rats and mice, and has been found to halt the progressive disease without causing tumors or other side effects, said chief scientific officer Bob Lanza at the biotech company Advanced Cell Technology Inc. (ACTC). "These cells have been really performing quite spectacularly in the animals. If we can see that in the human patients, we will hit a home run here," Lanza said. The trial, run and funded by the California-based company ACT, was allowed to go ahead after the U.S. Food and Drug Administration cleared its application to start a phase I study. Another company, Geron Corp. (GERN), began a similar trial in October, the first of its kind to test human embryonic stem cells in patients with spinal cord injuries. Scientists say the use of embryonic stem cells as a treatment for diseases such as cancer and other diseases holds great promise, but the process has drawn fire from religious conservatives and others who oppose it. Embryonic stem cell research is controversial because human embryos are destroyed in order to obtain the cells capable of developing into almost every tissue of the body. Using retinal cells derived from human embryonic stem cells, the latest treatment involves injecting the stem cells into the eyes of patients with Stargardt's Macular Dystrophy, a disease which affects around 25,000 people in the U.S. The 12 people in the initial study will have an advanced form of Stargardt's disease and don't expect to have their vision restored, since the test's main objective is to gauge safety. If ACT's trial shows that the treatment is safe, the process would be eventually be tested on younger patients to see if it could prevent blindness. The company has also applied for FDA permission to begin a wider trial on people with age-related macular degeneration, or vision loss, which affects as many as 30 million people in the U.S. and Europe. Stargardt's disease causes blindness by destroying the pigmented layer of the retina, called the retinal pigment epithelium, or RPE. After that follows degradation of photoreceptors, which are cells in the retina that detect light. Patients often experience blurry vision, difficulty seeing in low light and eventually most lose their ability to see at all. The disease can be inherited by a child when two parents carry the gene mutation that causes it. The treatment process being tested by ACT worked in animals by creating an abundance of new RPE cells, Lanza said. "Using stem cells, we can generate a virtually unlimited supply of healthy RPE cells, which are the first cells to die off in (Stargardt's) and other forms of macular degeneration," Lanza said. The process showed 100% improvement in rats' visual performance and "near-normal function" was also achieved in mice, both without negative side effects, he said. Researchers expect to see results in real-time due to the use of high resolution instruments that allow them to track the cells in the eye, with an assessment of the progress possible within weeks. "We should be able to know what's going on along the way," said Lanza. "It is quite conceivable we could see improvement within six weeks or so." "But we don't know. This has never been done to know how this is going to play out." (END) Dow Jones NewswiresNovember 22, 2010 00:27 ET (05:27 GMT)
